AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00827918
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching olanzapine tablets and MK-8998 capsules
Trial: NCT01968564
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar and other inert substances
Trial: NCT00131599
Drug: 5FU/LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU/LV
Trial: NCT03240783
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
Trial: NCT01196650
Drug: IN 10 003 formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01196650
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03001453
Drug: 0.25% Bupivacaine with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with epinephrine
Trial: NCT04148573
Drug: NFX88 - 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT04148573
Drug: NFX88 - 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT04148573
Drug: NFX88 - 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT04148573
Drug: PLACEBO - 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT03443492
Drug: Leucovorin(oral )
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention is administered to patients in this Arm.
Trial: NCT03443492
Drug: Leucovorin(IV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention is administered to patients in this Arm.
Trial: NCT01967524
Drug: Ropivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
Trial: NCT04238650
Drug: EU approved Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
Trial: NCT00789191
Drug: sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
Trial: NCT00002803
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002803
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00990691
Drug: Administration of a high dose of desipramine
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg.
Trial: NCT00990691
Drug: Administration of a low dose of desipramine
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg.
Trial: NCT00990691
Drug: Administration of a placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a daily dose of placebo
Trial: NCT03036163
Drug: PBTZ169 - 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of PBTZ169 (1 capsule) orally once in fasting state
Trial: NCT03036163
Drug: PBTZ169 - 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
Trial: NCT03036163
Drug: PBTZ169 - 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
Trial: NCT03036163
Drug: PBTZ169 - 320 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
Trial: NCT03036163
Drug: PBTZ169 - 640 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
Trial: NCT01436955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses
Trial: NCT01436955
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts receiving multiple oral doses
Trial: NCT04620408
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
Trial: NCT00629018
Drug: Bone Marrow Stimulation
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
Trial: NCT01283412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
Trial: NCT04337814
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral analgesic syrup (non-steroidal anti inflammatory drug)
Trial: NCT04337814
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup similar to Ibuprofen
Trial: NCT04337814
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream similar to EMLA
Trial: NCT02199236
Drug: concurrent capecitabine or 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.
Trial: NCT02932462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical product
Trial: NCT00578474
Drug: Moxidex otic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Trial: NCT00474500
Drug: Coca, Cola, Diet Coke
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01546428
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01895777
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Trial: NCT00309855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: im and orally
Trial: NCT00309855
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injections
Trial: NCT00223691
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO.Single dose.
Trial: NCT00223691
Drug: Ergotamine/ Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
Trial: NCT00223691
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-200 mg PO. Single dose
Trial: NCT00223691
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25, 50 or 75 mg, PO. Singe dose.
Trial: NCT00223691
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300, 600 or 900 mg, PO. Single dose.
Trial: NCT00223691
Drug: Carbidopa/levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
Trial: NCT00371111
Drug: Intravitreal injection of Avastin
RxNorm normalized name: Avastin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1.25 mg of Avastin and
Trial: NCT02395653
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
Trial: NCT02495662
Drug: PEG-liposomal prednisolone sodium phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone phosphate (DB14631)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal prednisolone
Trial: NCT02495662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT01832571
Drug: Once daily Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
Trial: NCT01261611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. injection on day 1 of treatment cycle 1.
Trial: NCT03372629
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching ID-085 capsules
Trial: NCT03536598
Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03536598
Drug: Valsartan 160 mg + Rosuvastatin 20 mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03736629
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 weeks of Azithromycin (250 mg) once daily by mouth
Trial: NCT03736629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01059396
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo propranolol / carvedilol
Trial: NCT02016183
Drug: Candesartan cilexetil / hydrochlorothiazide
RxNorm normalized name: candesartan cilexetil / hydrochlorothiazide Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil / hydrochlorothiazide combination tablets
Trial: NCT01224197
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mg capsule, one single dose
Trial: NCT01224197
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mg capsule, once daily for 5 days
Trial: NCT00257621
Drug: GW640385
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03006471
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one per day before breakfast during 12 weeks.
Trial: NCT00770328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO TID x 8 weeks
Trial: NCT00536133
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
Trial: NCT04797338
Drug: Synarel, 0.2 Mg/Inh Nasal Spray
RxNorm normalized name: Synarel, 0.2 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
Trial: NCT02744534
Drug: FACBC PET-CT Scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist.
Trial: NCT03315871
Drug: MSB0011359C (M7824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
Trial: NCT01130493
Drug: IPX066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental product
Trial: NCT00902304
Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
RxNorm normalized name: valsartan, amlodipine and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
Trial: NCT00902304
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As directed by investigator
Trial: NCT00902304
Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm
RxNorm normalized name: valsartan, amlodipine and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
Trial: NCT04095572
Drug: intravesical instillation with HA-CS
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
Trial: NCT03278015
Drug: S-1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
Trial: NCT03716856
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion
Trial: NCT04196179
Drug: ANG3070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
Trial: NCT04196179
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG-3070 placebo capsules visually match the drug product.
Trial: NCT01351285
Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
Trial: NCT03273296
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
Trial: NCT03830151
Drug: Hyperpolarized Carbon C 13 Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01200212
Drug: Taxane, Avastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Trial: NCT01200212
Drug: Taxane, Avastin, Xeloda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Trial: NCT00686166
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)
Trial: NCT04360265
Drug: Adjuvant Immunomodulatory (IM) Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
Trial: NCT06758167
Drug: XingpiJieyu formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
Trial: NCT06758167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, no therapeutic effect.
Trial: NCT01258309
Drug: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
Trial: NCT03051477
Drug: Helixor® M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hour IV infusion on Monday, Wednesday, and Friday of each week.
Trial: NCT01555216
Drug: Single injection posterior tibial nerve block
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of 0.5% ropivacaine
Trial: NCT01555216
Drug: Posterior tibial nerve catheter
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
Trial: NCT00702988
Drug: recFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU recFSH daily (reference group administered under protocol 38826)
Trial: NCT00272051
Drug: SR57746A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04063189
Drug: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
Trial: NCT02176551
Drug: Product 0405
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 0405 will be administered topically twice daily for 28 days.
Trial: NCT02176551
Drug: Placebo for Product 0405
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Trial: NCT02025881
Drug: Cyclophosphamide + Busilvex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose.
Trial: NCT04049175
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of CHF 6532